Loading clinical trials...
Loading clinical trials...
An Open-label Phase 1 Study to Evaluate Pharmacokinetics, Safety, and Tolerability of SY-2101 in Adult Patients With Acute Promyelocytic Leukemia
Conditions
Interventions
SY-2101
Arsenic Trioxide
Locations
8
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Northwestern Memorial Hospital
Chicago, Illinois, United States
John Hopkins University
Baltimore, Maryland, United States
University of Michigan
Ann Arbor, Michigan, United States
Weill Cornell Medical College
New York, New York, United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Start Date
September 17, 2021
Primary Completion Date
January 3, 2024
Completion Date
April 1, 2024
Last Updated
January 23, 2024
NCT04793919
NCT00003861
NCT01472107
NCT03624270
NCT04251754
NCT03751917
Lead Sponsor
Syros Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions